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Summary
Human B lymphocytes expressing the CD5 surface antigen (CD5+ B cells) constitute a subset
capable of producing polyspecific antibodies recognizing a variety of selfantigens. The repertoire
of antibodies produced by CD5+ and CD5 - B cells is different. However, it is not yet established
whether this distribution is reflected in different immunoglobulin variable region gene (IgV)
use. Rearrangement of heavy chain IgV (IgV) genes represents one of the first identifiable stages
in the maturation of B cells, and occurs in a developmentally ordered fashion. The repertoire
of IgV gene expression is highly restricted during fetal life but diversifies progressively after
birth. A high frequency of V gene use from the relatively small VIV gene family has previously
been demonstrated in human fetal liver B cells. In the present study, 102 B cell lines established
by Epstein-Barr Virus-transformation of separated CD5+ and CD5 - cord blood B cells, were
examined for the frequency of IgV expression using monoclonal antibodies to cross-reactive idiotypes
(CRI). The results demonstrate a relatively high frequency of VIV gene use (30%) in B cells
from cord blood. Furthermore, two mutually exclusive CRI associated with distinct subgroups
of the VIV family are segregated in their association with either subset of B cells. One CRI
is exclusively expressed in lines established from CD5 + B cells while the other is associated with
lines established from CD5- B cells.
D uring the past few years, heterogeneity within B lym-
phocyte populations has become increasingly apparent.
Several studies have demonstrated functional, physiological,
and developmental heterogeneity. Studies in the mouse sug-
gested that two separate lineages of B cells may exist (1). One
lineage, is defined by cell surface expression of the Ly-1 an-
tigen, characteristic of T lymphocytes, and the secretion of
polyspecific antibodies reactive with a variety of self antigens.
The second lineage lacks the Ly-1 antigen and produces anti-
bodies, mainly, to exogenous antigens (1). It is not clear, how-
ever, if the distinction is also reflected in antibody variable
region gene use by the Ly-1 + and Ly-1 - B cell subsets. This
question can be approachedby analysis ofvariable region gene
segment rearrangements, at the DNA level or through sero-
logical markers expressed on the protein products.
In humans, the majority of B lymphocytes in fetal liver,
cord blood, and a minority in adult peripheral blood and lymph
nodes express surface CD5 molecule, the human equivalent
of mouse Ly-1 (2).
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In the present study, we have used a number ofmAbs that
recognize cross-reactive idiotypes (CRI)t associated with in-
dividual V or V, gene family products to examine IgV gene
use in CD5+ and CD5 - B lymphocytes.
Materials and Methods
Preparation and Sorting ofB Lymphocytes.
￿
B Lymphocytes were
enriched from heparinized blood of three full-term donors by cen-
trifugation over Ficoll-Hypaque and rosetting using SRBCs (3).
The enriched B cell populations were stained simultaneously with
fluorescein-conjugated anti-CD20 (clone Leu-16) and PE-labeled
anti-CD5 (clone Leu-1) and sorted using a FACStar® (Becton Dick-
inson Immunocytometric Systems, Mountain View, CA). Lympho-
cytes displaying green fluorescence only (CD20', CD5 - cells) and
those displaying green and red fluorescence (CD20', CD5' cells)
were gated and sorted as CD5 - and CD5+ B cells, respectively.
'Abbreviation used in this paper: CRI, cross-reactive idiotypes.
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PE-labeled cells by FACSCAN (Becton Dickinson and Co.) .
Establishment ofEpstein-Barn Virus Transformed Cell Lines. Sorted
CD5' and CD5- B cells were infected with EBV using superna-
tant from the B95-8 marmoset line, and cultured in the presence
of 2 x 10^ irradiated (40 Gy) PBMCs (3). After culture for 2-7
wk, supernatants were harvested and assayed for the presence of
Ig using an ELISA. Culture plates with <33% of wells positive
for growth and immunoglobulin secretion were further evaluated
for the clonality ofthe Ig product using antibodies specific for the
IgM, IgG, IgA, K, and X isotypes. Cell lines positive for a single
heavy and light chain isotype only were investigated for the ex-
pression ofVI (G6 and G8), VIII (B6 and D12), and VIV (LC1,
R2.1A2, and 9G4) heavy chain subgroup associated CRI.
Production ofMurine Monoclonal Antibodies.
￿
The production and
specificity of all mAbs used has been reported (4-10). Antibodies
C7 and 17-109 have specificity for proteins expressing VIII sub-
group and a VXIIIb sub-subgroup associated CRI, respectively (5,
6). LCI (kindly provided by Dr. C. Winearls and Miss D. Brennan,
Hammersmith Hospital, London, UK) recognizesa CRI associated
with the VIV of an IgM rheumatoid factor paraprotein (7);
R2.1A2 (9), and 9G4 (10) specific for CRI expressed on 90% of
IgM paraproteins with cold agglutinin activity. Mab 9G4 was raised
in a Lou rat.
Human MonoclonalParaproteinsandDefinedB Cell Clones.
￿
Para-
proteins with cold agglutinin activity (from patients ODO and
HAW) were isolated from the serum of patients with cold agglu-
tinin disease, and specificity established using adult human O' red
blood cells at 41/z (10) . Rheumatoid factor paraproteins (from pa-
tients DIN and COR) were isolated from the serum of patients
having essential mixed cryoglobulinemia by affinity chromatography.
Paraproteins ofunknown specificity were isolated from the serum
of patients with Waldenstrom's macroglobulinemia by Sephacryl-
S200 gel filtration (Pharmacia, Uppsala, Sweden). Proteins from
patients ODO, DIN, COR, STR, and CAL were typed, serologi-
cally, for expression of heavy and light chain subgroups (11) and
kindly provided by Dr. Gregg Silverman (Research Institute of
Scripps Clinic, LaJolla, CA). Supernatants from the B cell clones
AB26, AB17 and AB44 were a kind gift from Dr. Don Capra
(Southwestern Medical Center, University of Texas, Dallas, TX).
The clones were established by EBV transformation of sorted
CD5' B lymphocytes from the peripheral blood of a normal in-
dividual. The variable region subgroup utilized was determined
by cDNA sequencing (12) .
Enzyme-Linked Immunosorbent Assay (ELISA). Microtitre
ELISA plates (Linbro, Flow Labs, High Wycombe, Bucks, UK),
sensitized with polyclonal sheep anti-human p chain were used
to bind IgM in the undiluted culture supernatant of B cell lines.
Purified proteins positive or negative for the expression of the probed
heavy and light chain isotypes and CRI were included in each assay
Lines expressing VXIII
to confirm specificity. Following threewashes with PBS containing
0.05% Tween 20 (PBS/T), murine mAb with specificity for tt,
«, and A, (clones AF6, 6ei, and C4, respectively; Unipath-Oxoid,
Bedford, UK) or CRI were added at 1/500 dilutions in PBS/T.
Bound mAb were revealed with horseradish peroxidaseconjugated
sheep anti-mouse or anti-rat Igs (Binding Site Limited, Bir-
mingham, UK). Plates were read using a Titretek Multiscan reader
(Flow Labs, High Wycombe, Bucks, UK) and OD value recorded
following subtraction ofbackground control values. The sensitivity
of the assays allowed detection ofantigen at a concentration of 5-10
ng/ml. Since Ig levels in the supernatants of the EBV lines were
500-5,000 ng/ml the assays provide further evidence suggestiveof
monoclonality and all profiles obtained were consistent with the
establishment of clones.
Statistical Analysis.
￿
The expression of CRI were compared in
2 x 2 tables using the chi-squared test (7C2) or Fisher's two-tailed
test depending on the number of samples examined.
Results and Discussion
Following infection with EBV and culture for 2-7 wk,
plates with <33% of wells positive for cell growth were
selected for study of the expression of CRI. This cut offpoint
provides for a statistical probability of monoclonality on the
basis of Poisson analysis of limiting dilution protocols (13).
Additionally, the criterion of expression of a single light and
heavy chain isotype was observed for all cell lines studied.
Furthermore, none ofthe cell linesexpressed CRI from more
than one V subgroup of heavy chains. The sensitivity of
the ELISA allowed for the detection of Ig produced by <1%
of the lymphocytes present; assuming they all have the same
capacity to produce Ig. Thus, while monoclonality is not
formally proven, all findings are consistent with such a con-
clusion. By these criteria a total of 102 cell lines were estab-
lished by EBV transformation of cord blood lymphocytes-
53 from the CD5+ population of B cells and 49 from the
CD5` population. Thirty-six of the 53 CD5+ cell lines ex-
pressed K light chain, while 17 expressed X light chain, a
tc/A ratio of 2:1, roughly the ratio found in circulating Igs.
For the CD5' cell lines a considerably lower tc/A ratio of
1:1.6 was observed.
Previous studies demonstrated a relatively high frequency
of VKIII subgroup expression in B cells from patients with
chronic lymphocytic leukaemia which express surface CD5
(14). Within our K-expressing CD5+ lines 12/36 (30%) ex-
pressed the VRIII subgroup of light chain (Table 1), a fre-
quency similar to the expected frequency of this light chain
Table 1 .
￿
VXIII Subgroup Expression within Cell Lines Established from CD5' or CD5- B Lymphocytes and Association with 17-109
CRI Expression
Selective Expression of a VIV Subfamily of Immunoglobulin Genes
Lines expressing 17-109
Cell line origin Total % of K lines Total % of VXIII lines % of K lines
CD5'
CD5 -
12 30
5 26
8
1
67
20
23
5Table 2.
￿
Reactivity ofMonoclonal Antibodies Specific for VHIV Associated CRI with Proteins from the VIV Family of Genes
Isotype
Protein
￿
V.-V, subgroup
￿
Specificity
￿
LC1
DIN
￿
IgM-VIV VKIII
￿
Rheumatoid factor
￿
+
COR
￿
IgM-VIV VKIII
￿
Rheumatoid factor
￿
+
STR
￿
IgM-VIV VKIII
￿
Unknown
￿
+
CAL
￿
IgM-VIV VKII
￿
Unknown
￿
+
ODO
￿
IgM-VIV VKIII
￿
Cold agglutinin
HAW
￿
IgM-VIV VKII
￿
Cold agglutinin
AB26
￿
IgM-VIV V),
￿
Polyreactive
AB17
￿
IgG3-VIV VKIII
￿
Polyreactive
AB44
￿
IgA-VIV VxI
￿
Polyreactive
subgroup in polyclonal IgM. The proportion of VKIII in the
K-expressing CD5 - lines was similar (26%) (Table 1).
However, the frequency of VKIII light chains expressing the
17-109 CRI was higher (Fisher's two-tailed probability =
0.13) in the CD5+ lines compared with the CD5 - ones.
V gene usage within the cell lines was investigated using
a panel of mAbs specific for V subgroup associated CRI.
The significant finding was expression of VIV-associated
CRI. This is of particular interest because recent studies by
Sanz et al. (12) have demonstrated a remarkablyhigh frequency
of VIV gene use in B cell clones established by EBV trans-
formation of CD5+ B cells from the peripheral blood of
normal individuals. Furthermore, due to the small number
of genes within this family (ti10) and the high degree of
internal homology (at least 91.5% between the most distant
members to a consensus VIV sequence) it is probable that
the germline gene repertoire would be represented by rela-
tively few CRI.
In this study we applied three anti-CRI reagents, two of
which appear to recognize the same or mutually inclusive
CRI (R2.1A2 and 9G4). The third reagent (LC1) recognizes
a CRI that is mutually exclusive to R2.1A2 and 9G4 (Table
2). Although neither CRI could be formally assigned to
reported VIV genes, association with some germline genes
is possible, on the basisofthe present studies and recent studies
ofcold agglutinins (11) and polyreactive antibodies (12). Thus,
the CRI recognized by LCl may be a phenotypic marker
for the 71-2 and 71-4 genes and related genes, whereas
R2.lA2/9G4 may be markers for the 4-21 and related genes.
Our analyses reveal that: (a) The representation of VIV
genes in these B cell lines is considerably higher than would
be predicted for this relatively small family of genes. (b) A
relatively higher but insignificant proportion of CD5 + cell
lines express VIV genes compared to their CD5 - counter-
parts (35% vs. 28%; X2 = 0.62, p > 0.1) . (c) Remarkably,
whereas 13/53 (24%) cell lines derived from the CD5 +
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Reactivity with anti-VIV CRI
R2.1A2 9G4
Reactivity of monoclonal anti-CRI was determined in ELISA. V and VK subgroup of proteins DIN, COR, STR, CAL, ODO, and HAW were
assigned by immunoblot analysis with peptide induced reagents. Expression of VKIII subgroup was confirmed by reactivity with monoclonal anti-
body C7. V and VL of proteins AB26, AB17, and AB44 were assigned by DNA sequence analysis.
population coexpressed both R2.1A2 and 9G4, no CD5 `
cell lines expressed either of these CRI (Table 3) (X2 = 13.8,
p < 0.001). (d) Conversely, 14/49 (28%) CD5 - lines ex-
pressed LCl, while only 6/53 (11%) CD5+ lines expressed
this CRI (X2 = 4.8, p < 0.05).
Thus, it appears that a significant proportion of CD5+
B cell lines produce IgM derived from a single gene, or a
small number of genes within the VIV family for which
a CRI associated with anti-I-carbohydrate antigen specificity
is a phenotypic marker. Both R2.1A2 and 9G4 were coex-
pressed on the same molecules and were associated with K
light chain expression in 9/13 (70%) of the cell lines. How-
ever, none of the cell lines could be demonstrated to express
theVKIII epitope C7 or 17-109 together with R2.1A2 and
9G4. This appears to be in contrast to the observed associa-
tion of VIV heavy chains and VKIII light chains in cold ag-
glutinins (15).
Table 3.
￿
VIV-associated CRI Expression in CD5' and
CD5- Cell Lines Establishedfrom Cord Blood Lymphocytes
Cell line
origin Total no.
No.
LC1
(%) lines expressing
R2.1A2 9G4
CD5+
IgM x 36 4(11%) 10(28%) 10 (28%)
IgM X 17 2 (5 .5%) 3 (11%) 3 (11%)
Total 53 6 (11%) 13 (24%) 13 (24%)
CD5 -
IgM is 19 5 (26%) 0 (0%) 0(0%)
IgM X 30 9 (30%) 0(0%) 0(0%)
Total 49 14 (28%) 0(0%) 0 (0%)In this study the expression of heavy chains from the
VIV family was associated with antibodies that were poly-
reactive (MacKenzie, L.E., R.A. Mageed, and P.M. Lydyard,
unpublished observations). However, VIV gene family
usage was not seen to be a prerequisite for polyreactivity since
heavy chains from other gene families were also expressed
in polyreactive antibodies in both CD5' and CD5 - cell
lines.
The significant findings of the present study are: (a) The
high frequency of VIV gene family expression observed in
cell lines established from cord blood B cells, and (b) The
selective expression of a subset of VIV genes, characterized
by the expression of the R2.1A2 and 9G4 CRI, within
CD5+ B cells.
The VIV gene family is composed of a maximum of
about 10 members, and the incidence of paraproteins derived
from this gene family is low in Waldenstrom's macro-
globulinemia and multiple myeloma (12) . In contrast the fre-
quency of VIV gene usage in fetal liver B cells has been es-
timated to be 21% (16), a frequency not dissimilar to the
30% observed for the cord blood derived B cell lines.
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